IMP 321

Drug Profile

IMP 321

Alternative Names: EDP-202; hLAG-3Ig; ImmuFact IMP321; IMP321; LAG-3-Ig-fusion-protein; LAG-3Ig; sLAG-3-Ig

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immutep
  • Developer Immutep; Krankenhaus Nordwest; Prima BioMed
  • Class Adjuvants; CD antigens; Immunoglobulins; Recombinant fusion proteins
  • Mechanism of Action Antigen presenting cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Malignant melanoma; Solid tumours
  • No development reported Renal cell carcinoma

Most Recent Events

  • 21 Sep 2017 Chemical structure information added
  • 05 Sep 2017 Prima BioMed has patent protection for IMP 321 for the treatment of Infections in Japan
  • 15 Aug 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Germany (Intratumoural) (Intraperitoneal) (NCT03252938)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top